

**IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF PENNSYLVANIA**

IN RE: GLUCAGON-LIKE	:	CIVIL ACTION
PEPTIDE-1 RECEPTOR AGONISTS	:	
(GLP-1 RAS) PRODUCTS	:	
LIABILITY LITIGATION	:	MDL No. 3094
_____	:	24-md-3094
	:	01-md-3094
THIS DOCUMENT RELATES TO:	:	
	:	HON. KAREN SPENCER MARSTON
<i>ALL ACTIONS/ALL CASES</i>	:	

CASE MANAGEMENT ORDER NO. 32

Fifth Amended Scheduling Order for Cross Cutting Issues 2 and 3

AND NOW, this 30th day of April, 2026, upon consideration of the Novo Defendants’ unopposed request to extend the case management deadlines as to Cross Cutting Issues 2 and 3, it is **ORDERED** that for good cause shown, the request is **GRANTED**, and the deadlines for Cross Cutting Issues 2 and 3 are **AMENDED** as follows:

May 19, 2026	Deadline for the submission of motions to exclude expert opinions under Rule 702 and initial briefs
May 19, 2026	Deadline for the submission of summary judgment motions and initial briefs
June 17, 2026	Deadline for the submission of briefs in opposition to Rule 702 motions
June 30, 2026	Deadline for the submission of briefs in opposition to summary judgment motions
July 15, 2026	Deadline for the submission of reply briefs in support of Rule 702 motions

August 7, 2026	Deadline for the submission of reply briefs in support of summary judgment motions
September 10-18, 2026	Hearing on Rule 702 Motions in Courtroom 16B. Each day, the Court will begin at 9:00 a.m.

IT IS SO ORDERED.

/s/Karen Spencer Marston

KAREN SPENCER MARSTON, J.